TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient rated ulnar nerve evaluation (PRUNE) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Events Safety Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Adequation to ANSM 2015 guidelines of antibiotics prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of success of the first vein puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of multiparametric assessment of mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neuropsychological performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum GFAP concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum NSP concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum pNfH concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum VILIP-1 concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of colorectal polyps and neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse event evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: pre KiFDA-AR ver 2.0 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the mean score of distress (Hospital Anxiety Depression Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the mean score of distress (Psychological distress scale used in the Quebec Health Survey)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative sputum cultures at completion of eight weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Permanent discontinuation of assigned study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy-related peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Consent to psychological screen rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate corrected QT interval length (QTcI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Brief Illness Perception Questionnaire (Brief IPQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Oral Health Impact Profile 14
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of Epidural Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peroperative hemodynamic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: live birth rate of offspring
Endpoint domain: Mortality/survival
Primary endpoint: Monocular Distance Corrected Near Visual Acuity (DCNVA) at 40 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Adverse Events vs ISO SPE Rates (6-Month Persistent Medical Complications/Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Adverse Events vs ISO SPE Rates (6-Month Cumulative Medical Complications/Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of electromagnetic interference
Endpoint domain: Adverse events/effects
Primary endpoint: change in Melbourne Assessment 2 (MA2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Box and Block Test (BBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Pediatric Motor Activity Log-Revised (PMAL-R)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Cognitive Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Verbal Fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in core symptoms of AN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of tasimelteon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of tasimelteon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skeletal muscle protein fractional synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of participants with 50% decrease in Pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three months average blood glucose (A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation of bacterial load of Positive Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Radiological Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Complications Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of subjects with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Walking knee pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum Free Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Best response (complete response /complete response with incomplete recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slow Ventricular Tachycardia Episodes Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial Fibrillation Episodes Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MDS-UPDRS scale on on and off state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) (Arabic version)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: White matter severity by MRI brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: first-pass success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-tidal oxygen fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color Trail Test (CTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Box-and-Block Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Timed-Up-and-Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Postural sway while standing quietly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Voluntary postural sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Trail Making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoral measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extraoral measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Reduction in Contracture to 5° or Less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Joint Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of tumoural cells expression IDO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Modification of tumoural T Cells infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PG-YBOCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP / Oxygen ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amplitude of patellofemoral angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation of patellofemoral tilt angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance of lateral displacement of the patella
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of allogeneic erythrocyte transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients exposed to allogeneic erythrocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time of progression to type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of eligible participants recruited and randomized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success at 24-hour patient global assessment of pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number and frequency of adverse events Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting product characteristics as barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration-time curve (AUC) of Q-GRFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Para-cellular permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gap junction protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation molecule expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Digestive discomfort degree
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Function at hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of participants positive for Group A Streptococcus by Sofia rapid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants negative for Group A Streptococcus by Sofia rapid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants positive for Group A Streptococcus by QuickVue rapid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants negative for Group A Streptococcus by QuickVue rapid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in 6-Minute Walk Test Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Rodnan Total Skin Thickness Score (mRTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of BCVA by log MAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Korean version of Western Ontario and McMaster Universities Arthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum S100B protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh pain measured by Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Length of acute hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: composite of death or repeat hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Cholestasis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: incidence of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: EORTC-QLQC30 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in heart rate peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ever having vaginal sex in the past 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: risk of exposure to sexually transmitted infections in the past 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ever having unprotected vaginal sex in the past 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Axial Rotation (AR) During Deep Knee Bend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Weight-bearing Flexion During Deep Knee Bend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medial Condyle Translations During Deep Knee Bend Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lateral Condyle Translations During Deep Knee Bend Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Endothelial Cell Protein Expression p47phox
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reaching Clinical Long Term Component Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Treg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in mRNA expression of cytokines related to Treg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in secretion levels of cytokines related to Treg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opioid requirements during first postoperative TES session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores during first postoperative TES session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative opioid consumption during recovery room stay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in patient reported VM pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient reported VM impact on daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in patient reported efficacy of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of malaria infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Postoperative Intra-abdominal Abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Dermatomes With Complete Motor Block of the Upper Extremities at 30 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Failure to pass gestational sac
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cumulative drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dysplasia detection rate at first surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neoplasia detection rate at first surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dysplasia detection rate at second surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neoplasia detection rate at second surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Additive prognostic value of 6MWT to the RCRI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Rating Scale for Depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: White Blood Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: downstaging rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance of diagnostic aids for oral cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disembowelment number
Endpoint domain: Adverse events/effects
Primary endpoint: Physical Exam Findings
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical composite outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical global improvement in sexual function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median maximum change in FEV1 and FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage change in FEV1 and FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Standardized Area Under the Curve (AUC) for FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence and Severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of acute rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean number of episodes of acute diarrheal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of acute diarrheal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nocturnal bruxism severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal bruxism muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of programmed death-1 (PD-1) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: estimated blood loss (milliliters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change From Baseline in Morning Pre-dose Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total adiponectin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in inflammatory/immune biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline Multiple Organ Dysfunction (MOD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction-expulsion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Complete Resection (R0 Resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pupil diameter variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of contaminated duodenoscopes
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of depressed moods
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of parenting stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the ExoDx Prostate IntelliScore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biomarkers of cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Six-minute Walk Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Least Squares Mean Difference in Binocular UCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between Zinc concentration and prostate cancer grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Headache Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes